You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

NAPROSYN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Naprosyn patents expire, and when can generic versions of Naprosyn launch?

Naprosyn is a drug marketed by Atnahs Pharma Us and is included in two NDAs.

The generic ingredient in NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the naproxen profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Naprosyn

A generic version of NAPROSYN was approved as naproxen by GRANULES on December 21st, 1993.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NAPROSYN?
  • What are the global sales for NAPROSYN?
  • What is Average Wholesale Price for NAPROSYN?
Summary for NAPROSYN
Drug patent expirations by year for NAPROSYN
Drug Prices for NAPROSYN

See drug prices for NAPROSYN

Recent Clinical Trials for NAPROSYN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwestern Medical GroupPhase 2
Shirley Ryan AbilityLabPhase 2
Western University, CanadaN/A

See all NAPROSYN clinical trials

Pharmacology for NAPROSYN

US Patents and Regulatory Information for NAPROSYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Atnahs Pharma Us NAPROSYN naproxen SUSPENSION;ORAL 018965-001 Mar 23, 1987 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NAPROSYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ⤷  Sign Up ⤷  Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-004 Apr 15, 1982 ⤷  Sign Up ⤷  Sign Up
Atnahs Pharma Us NAPROSYN naproxen TABLET;ORAL 017581-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for NAPROSYN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 122012000052 Germany ⤷  Sign Up PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 122012000051 Germany ⤷  Sign Up PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0984957 PA2011005,C0984957 Lithuania ⤷  Sign Up PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.